Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.

NCT06087120 is registered in ClinicalTrials.gov with Gene Solutions as lead sponsor.

NCT NCT06087120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06087120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.
Lead sponsor
Gene Solutions
Phase
Observational
Overall status
Recruiting
Start date
September 16, 2023
Completion date
December 31, 2025
Enrollment
125 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, her2-positive breast cancer, stage ii breast cancer, stage iii breast cancer, triple negative breast cancer